Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc.（TTNP）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · TTNP · 截至 2026年6月8日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
2
近12个月
买卖比
1.00
Buy/Sell (by trades)
整体情绪
Titan Pharmaceuticals, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
TTNP 季度内部人买卖趋势
TTNP 内幕交易卖出 · TTNP 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · TTNP CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
TTNP 高管卖出股份 · TTNP 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Oct 1, 2025 | Ben-Tzvi Avraham Director | Other | 3,313 | — | Form 4 |
| Mar 18, 2024 | Choong Choon Hau 10 percent owner | Other | 54,132 | — | Form 4 |
| Oct 25, 2023 | NATAN DAVID Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | McMurdo Matthew Charles Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | Greenberg Eric Howard Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | Beebe Katherine President and COO · Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | Ben-Tzvi Avraham Director | Award | 16,250 | — | Form 4 |
| Jul 26, 2023 | Greenberg Eric Howard Director | Award | 50,000 | — | Form 4 |
| Jul 26, 2023 | Lazar David E. CEO · Director | Award | 100,000 | — | Form 4 |
| Jul 26, 2023 | Ben-Tzvi Avraham Director | Award | 50,000 | — | Form 4 |
| Jul 26, 2023 | Beebe Katherine President and COO · Director | Award | 50,000 | — | Form 4 |
| Jul 26, 2023 | McMurdo Matthew Charles Director | Award | 50,000 | — | Form 4 |
| Jan 28, 2022 | MCNAB JAMES R Director | Other | 51,021 | $2.55B⚡ | Form 4 |
| Oct 19, 2018 | Recli Federico Seghi Director | Purchase | 200,000 | $82K | Form 4 |
| Sep 24, 2018 | Recli Federico Seghi Director | Purchase | 500,000 | $114K | Form 4 |
| Sep 21, 2018 | MACFARLANE M DAVID Director | Purchase | 80,000 | $20K | Form 4 |
| Sep 21, 2018 | BHONSLE SUNIL See Remarks · Director | Purchase | 300,000 | $75K | Form 4 |
| Sep 21, 2018 | MCNAB JAMES R Director | Purchase | 200,000 | $50K | Form 4 |
| Sep 21, 2018 | Rubin Marc Executive Chairman · Director | Purchase | 400,000 | $100K | Form 4 |
| Sep 21, 2018 | Akers Joseph A Director | Purchase | 200,000 | $50K | Form 4 |
| Jul 19, 2016 | Akers Joseph A Director | Purchase | 5,000 | $23K | Form 4 |
| Jul 18, 2016 | Akers Joseph A Director | Purchase | 8,000 | $40K | Form 4 |
| Jul 18, 2016 | BHONSLE SUNIL President and CEO · Director | Purchase | 10,000 | $50K | Form 4 |
Rubin Marc
Executive Chairman · Director
日期
Sep 21
股数
400,000
均价
$0.25
总金额
$100K
BHONSLE SUNIL
President and CEO · Director
日期
Jul 18
股数
10,000
均价
$4.96
总金额
$50K
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 TTNP 内幕交易
TTNP 内幕交易
Titan Pharmaceuticals, Inc.（TTNP）内幕交易数据来源于公司内部人（包括Ben-Tzvi Avraham (Director)）提交的SEC Form 4申报文件。过去12个月内，1位内部人向SEC提交了交易申报。TTNP内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Titan Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
TTNP 内幕交易 · 5个问题Titan Pharmaceuticals, Inc.（TTNP）的内部人包括高管和董事，如Ben-Tzvi Avraham (Director)等。过去12个月内，1位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026